Recombinant Anti-68kDa Neurofilament/NF-L antibody [EP675Y] - BSA and Azide free (ab236122)
Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EP675Y] to 68kDa Neurofilament/NF-L - BSA and Azide free
- Suitable for: WB, IP
- Reacts with: Mouse, Rat, Human
Related conjugates and formulations
Overview
-
Product name
Anti-68kDa Neurofilament/NF-L antibody [EP675Y] - BSA and Azide free
See all 68kDa Neurofilament/NF-L primary antibodies -
Description
Rabbit monoclonal [EP675Y] to 68kDa Neurofilament/NF-L - BSA and Azide free -
Host species
Rabbit -
Tested applications
Suitable for: WB, IPmore details -
Species reactivity
Reacts with: Mouse, Rat, Human -
Immunogen
Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
-
Positive control
- IP: Neurofilament/NF-L in Human brain lysate; WB: Human, rat, and mouse brain tissue lysates.
-
General notes
ab236122 is the carrier-free version of ab52989.
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. The carrier-free buffer and high concentration allow for increased conjugation efficiency.
This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our conjugation kits for antibody conjugates that are ready-to-use in as little as 20 minutes with <1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
This product is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar® is a trademark of Fluidigm Canada Inc.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C. Do Not Freeze. -
Storage buffer
pH: 7.2
Constituent: PBS -
Carrier free
Yes -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
EP675Y -
Isotype
IgG -
Research areas
Associated products
-
Alternative Versions
-
Conjugation kits
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab236122 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
Use at an assay dependent concentration. Detects a band of approximately 68 kDa (predicted molecular weight: 61 kDa).
|
|
IP |
Use at an assay dependent concentration.
|
Notes |
---|
WB
Use at an assay dependent concentration. Detects a band of approximately 68 kDa (predicted molecular weight: 61 kDa). |
IP
Use at an assay dependent concentration. |
Target
-
Function
Neurofilaments usually contain three intermediate filament proteins: L, M, and H which are involved in the maintenance of neuronal caliber. -
Involvement in disease
Defects in NEFL are the cause of Charcot-Marie-Tooth disease type 1F (CMT1F) [MIM:607734]. CMT1F is a form of Charcot-Marie-Tooth disease, the most common inherited disorder of the peripheral nervous system. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathy or CMT1, and primary peripheral axonal neuropathy or CMT2. Neuropathies of the CMT1 group are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. CMT1F is characterized by onset in infancy or childhood (range 1 to 13 years).
Defects in NEFL are the cause of Charcot-Marie-Tooth disease type 2E (CMT2E) [MIM:607684]. CMT2E is an autosomal dominant form of Charcot-Marie-Tooth disease type 2. Neuropathies of the CMT2 group are characterized by signs of axonal regeneration in the absence of obvious myelin alterations, normal or slightly reduced nerve conduction velocities, and progressive distal muscle weakness and atrophy. -
Sequence similarities
Belongs to the intermediate filament family. -
Domain
The extra mass and high charge density that distinguish the neurofilament proteins from all other intermediate filament proteins are due to the tailpiece extensions. This region may form a charged scaffolding structure suitable for interaction with other neuronal components or ions. -
Post-translational
modificationsO-glycosylated.
Phosphorylated in the Head and Rod regions by the PKC kinase PKN1, leading to inhibit polymerization. - Information by UniProt
-
Database links
- Entrez Gene: 4747 Human
- Entrez Gene: 18039 Mouse
- Entrez Gene: 83613 Rat
- Omim: 162280 Human
- SwissProt: P07196 Human
- SwissProt: P08551 Mouse
- SwissProt: P19527 Rat
- Unigene: 521461 Human
see all -
Alternative names
- 68 kDa neurofilament protein antibody
- 68kDa Neurofilament antibody
- 68kDa neurofilament protein antibody
see all
Images
-
All lanes : Anti-68kDa Neurofilament/NF-L antibody [EP675Y] (ab52989) at 1/1000 dilution (Purified)
Lane 1 : Human brain lysate
Lane 2 : Mouse brain lysate
Lane 3 : Rat brain lysate
Lysates/proteins at 15 µg per lane.
Secondary
All lanes : Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 61 kDa
Observed band size: 68 kDa why is the actual band size different from the predicted?This data was developed using ab52989, the same antibody clone in a different buffer formulation.
Blocking buffer: 5% NFDM/TBST
-
Purified ab52989 at 1:20 dilution (2µg) immunoprecipitating 68kDa Neurofilament/NF-L in Human brain lysate.
Lane 1 (input): Human brain lysate 10µg
Lane 2 (+): ab52989 + Human brain lysate.
Lane 3 (-): Rabbit monoclonal IgG (ab172730) instead of ab52989 in Human brain lysate.
VeriBlot for IP Detection Reagent (HRP)(ab131366) (1:1000 dilution) was used for Western blotting.
Blocking Buffer and concentration: 5% NFDM/TBST.
Diluting buffer and concentration: 5% NFDM/TBST.
Observed band size: 68 kDa
Protocols
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
Datasheets and documents
-
Datasheet download
Certificate of Compliance
References (1)
ab236122 has been referenced in 1 publication.
- Yang X et al. Transgenic inhibition of astroglial NF-?B restrains the neuroinflammatory and neurodegenerative outcomes of experimental mouse glaucoma. J Neuroinflammation 17:252 (2020). PubMed: 32859212